The researchers wanted to see if supramarginal resection (SMR) of FLAIR-hyperintense tumors beyond the contrast-enhanced (CE) area affects overall survival (OS) in patients with isocitrate dehydrogenase–wild-type (IDH-wt) glioblastoma after gross-total resection using a multicenter observational cohort study (GTR). The medical records of 888 patients under the age of 18 who had a GBM removed between January 2011 and December 2017 were examined. Volumetric measures of the CE tumor and the surrounding FLAIR-hyperintense tumor were taken, clinical factors were collected, and researchers investigated relationships with OS.
About 101 individuals met the inclusion criteria with newly diagnosed IDH-wt GBM who had GTR of the CE tumor. In multivariate analysis, preoperative Karnofsky Performance Status greater than or equal to 70 (HR 0.47; 95% CI 0.27–0.89; P=0.006), MGMT promoter methylation (HR 0.63; 95% CI 0.52–0.99; P=0.044), an encore associated with shorter OS, but preoperative Karnofsky Performance Status greater than or equal to 70 (HR Finally, 20% SMR was the lowest %age related with improv 0.01), but SMR levels beyond 60% showed no effect (HR 0.74; 95% CI 0.45–1.21; P=0.234). In patients with IDH-wt GBM who undergo CE tumor GTR, SMR is linked to a longer survival time. SMR of the CE tumor of at least 2% was linked to a longer survival time. However, an SMR of more than 60% did not affect survival.